Goldman Sachs initiated coverage of Charles River with a Buy rating and $290 price target. The analyst initiated coverage of the contract research organizations sector, believing the industry represents an undervalued approach to gain exposure to a potential recovery in large pharma and emerging biotech spend. The firm sees Charles River as the dominant company in the preclinical space, allowing for effective pricing and direct leverage to innovation and biopharma spend.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River announces launch of VCG initiative with Sanofi
- Charles River participates in a conference call with JPMorgan
- Charles River price target lowered to $228 from $260 at TD Cowen
- Charles River price target lowered to $270 from $282 at Baird
- Charles River files automatic mixed securities shelf